Quick answer
The KLOW stack is a four-peptide blend (GHK-Cu, KPV, BPC-157 and TB-500), so purity testing has to resolve and identify each component separately; one headline percentage for the whole mixture is not enough.
- Method pair: reversed-phase HPLC for resolution and area-percent purity, plus mass spectrometry to assign each peak
- Expected masses: free GHK ≈ 340 Da, KPV ≈ 342 Da, BPC-157 ≈ 1,419 Da; TB-500 depends on the exact sequence supplied
- Listed on V8's product page: 80 mg lyophilized blend, ≥98% HPLC purity
- Watch-out: GHK and KPV differ by only about 2 Da, so retention time and mass accuracy must be used together
- Research use: For laboratory research use only; not for human consumption.
Why a blend changes the testing problem
For laboratory research use only; not for human consumption.
Because the KLOW stack is a combination preparation rather than a single molecule, meaningful purity testing means verifying each component peptide independently, not just confirming that something is present in the mixture. The blend contains KPV, GHK-Cu, BPC-157 and TB-500, molecules that span a wide size range and differ considerably in polarity. A blend certificate therefore has more to demonstrate than a single-peptide report does: that every intended component is present, that none has been substituted, that each is individually pure, and that the stated composition matches what was weighed in.
| Component | Type | Approximate mass | Chromatographic behavior |
|---|---|---|---|
| GHK (from GHK-Cu) | Tripeptide, Gly-His-Lys, copper-binding | ≈ 340 Da as free peptide | Small and polar; elutes early |
| KPV | Tripeptide, Lys-Pro-Val | ≈ 342 Da | Small and polar; elutes early, near GHK |
| BPC-157 | 15-residue peptide | ≈ 1,419 Da | Intermediate retention |
| TB-500 | Thymosin beta-4-related peptide; form depends on supplier | Full-length thymosin beta-4 is about 4,960 Da; shorter fragments are much smaller | Later elution for longer sequences |
The full-length figure for thymosin beta-4 is the basis for the "more than tenfold" size spread inside this blend; if a shorter TB-500 fragment is supplied, the spread is smaller and the expected mass on the COA changes accordingly. This is why the COA should state which TB-500 sequence it refers to. Component background is in the KLOW stack research overview.
Reversed-phase HPLC
HPLC on a multi-component preparation resolves each peptide as a separate peak, letting a lab confirm that all intended components are present in roughly their expected relative proportions. General interpretation is in understanding HPLC purity. The small, polar tripeptides elute early, while the longer and more hydrophobic sequences come off the column later, so the four components are usually well separated.
Under the acidic mobile phases typical of these methods, copper generally dissociates from GHK-Cu and the peptide is observed as free GHK. The chromatogram therefore reports the peptide ligand, not the copper complex; copper content, where reported, is measured by a separate technique. Relative peak areas give only an approximate guide to proportion, because each peptide absorbs UV light differently: absorbance near 214 nm scales largely with the number of peptide bonds, so a 15-residue peptide gives a far larger signal per mole than a tripeptide.
Reading the KLOW stack chromatogram
The headline number on a report comes from integrating the chromatogram: main-peak area as a share of total peak area, measured by UV absorbance near 214–220 nm. For a blend, the useful reading is per-component. Reviewers typically check that:
- the gradient is slow enough to separate the two early-eluting tripeptides cleanly;
- each of the four principal peaks is sharp and symmetrical;
- the baseline returns to zero between peaks;
- small peaks are integrated and reported individually, not merged;
- method conditions are printed on the report so a later re-test can be compared against it.
A chromatogram supplied without its method conditions is much harder to compare against a later re-test of the same lot.
Mass spectrometry for identity
Mass spectrometry independently confirms each resolved peak's identity, which matters more for a stack than for a single-compound lot because a missing or substituted component could otherwise go unnoticed. The distinction from HPLC is explained in HPLC vs. mass spectrometry.
Expected values help when reading the spectrum: roughly 340 Da for GHK as the free tripeptide, 342 Da for KPV, and 1,419 Da for BPC-157, with the TB-500 value depending on the exact sequence supplied. GHK and KPV differ by only about 2 Da, so adequate mass accuracy, together with their different retention times, is needed to assign them correctly. Larger peptides appear as multiply charged ions, which software converts back to a neutral mass, so a report should show the deconvoluted value alongside the raw spectrum.
| Check | What a consistent result looks like | What would be a concern |
|---|---|---|
| Number of principal peaks | Four, each assignable by mass | Fewer than four, or an unassigned major peak |
| GHK vs. KPV assignment | Separate retention times and masses near 340 and 342 Da | One merged peak or an ambiguous assignment |
| BPC-157 mass | ≈ 1,419 Da | Values lower by one or more residue masses (truncation) |
| TB-500 mass | Matches the sequence stated on the COA | No sequence stated, or no matching mass |
| Oxidation signals | No +16 Da satellite peaks | Recurring +16 Da species on methionine-containing sequences |
Why component-level verification matters
KLOW's research value depends on studying its component parallel pathways together; if one component is absent or degraded, the combination being studied is not actually the intended one. That would undermine any comparison with single-compound work on related peptides such as GHK-KPV or with the broader context in peptide blends and research stacks.
Blends also raise a degradation question that single peptides do not: components age at different rates. A methionine-containing sequence may oxidize while its neighbors remain intact, so re-analysis of stored material should look at every peak. Thymosin beta-4 contains methionine, and oxidation shows up as a +16 Da species; BPC-157, GHK and KPV contain none. Each component's structure is described in the KLOW stack chemical composition article.
What an HPLC percentage leaves out
Area-percent purity says how much of the peptide material is the intended sequence; it does not say how much of the powder is peptide. Counter-ions such as acetate or trifluoroacetate and bound water add mass without absorbing at the detection wavelength. Where assay concentrations need to be exact, net peptide content is the relevant figure. For a blend there is a second layer: the composition (mg of each component per vial) is a separate claim from purity, and only a component-level quantitation against reference standards can support it.
The peptide calculator converts vial contents and diluent volume into a working concentration. As a worked example, 80 mg of total blend in 4 mL of diluent is 20 mg/mL of combined material; the concentration of any single component depends on its share of the blend, which is exactly the number the COA should state.
Documentation to expect
A lot-specific certificate of analysis covering each component peptide; see how to read a CoA. When checking a KLOW Stack certificate, confirm that it carries:
- a batch identifier that matches the vial in hand;
- an HPLC trace, not just a typed percentage;
- observed and expected mass values from the mass-spec run, for each component;
- the analysis date and the testing laboratory's details.
Batch records can be looked up on the CoA page. The V8 listing for the KLOW Stack research vial describes an 80 mg lyophilized blend at ≥98% HPLC purity, and states that identity and sequence information is reported on the certificate of analysis where published. Independent confirmation is discussed in third-party testing explained.
Keeping a verified lot verified
Analytical results are a snapshot. Once a vial of KLOW Stack is opened, humidity, temperature swings and light exposure begin to matter, and a solution is less stable than the lyophilized cake it came from. The product page specifies refrigeration at 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light. Good practice is to aliquot after reconstitution to avoid freeze-thaw cycling and to note preparation dates so that any unexpected assay behavior can be traced back to material age. General handling is covered in GLOW peptide reconstitution and storage, which describes a related multi-peptide blend, and the relationship between stacks is compared in GLOW vs. KLOW vs. Wolverine.
Research Use Only. For laboratory research use only; not for human consumption. Not for veterinary or diagnostic purposes. This article is research education, not usage guidance.
KLOW stack purity testing FAQ
How many peaks should a KLOW stack chromatogram show?
Four principal peaks, one per component, each assignable by mass. Additional small peaks represent impurities or degradation products and should be integrated and reported.
Can peak area ratios be read as mass ratios?
Only roughly. UV response depends on each peptide's length and aromatic content, so quantifying the proportion of each component requires calibration against individual reference standards.
Why is GHK detected without its copper?
Acidic reversed-phase conditions typically strip the metal from the complex, so the chromatogram and spectrum show the free tripeptide. Copper content, where reported, is measured by a separate technique.
Why are GHK and KPV hard to tell apart by mass?
Their masses differ by only about 2 Da (roughly 340 and 342). Assigning them correctly needs both adequate mass accuracy and the fact that they elute at different retention times.
Does a single blend purity figure verify all four peptides?
No. A single figure can hide a missing or degraded component. A blend report should give identity and purity for each peptide, plus a statement of composition.
Why might one component degrade faster than the others?
Sequences differ in susceptible residues. Methionine can oxidize (+16 Da), for example, while peptides without it remain unchanged, so a stored blend should be re-analysed across all peaks.
What does the V8 product page state about purity?
The KLOW Stack page lists an 80 mg lyophilized blend with ≥98% HPLC purity and says batch documentation is published on the site; check the COA page for the lot you hold.
Is net peptide content the same as purity?
No. Purity is the share of peptide material that is the correct sequence; net peptide content is the share of the powder that is peptide at all, after counter-ions and water.